Sanjiv Patel, Relay Therapeutics CEO
September 8, 2022 06:18 AM EDT
R&D

#ES­MO22: Re­lay Ther­a­peu­tics joins the win­ner's cir­cle this week­end as up­dat­ed can­cer da­ta win ap­plause

John Carroll

Editor & Founder

PARIS — Re­lay Ther­a­peu­tics had steadi­ly raised the bar ahead of ES­MO for RLY-4008, its bile duct can­cer drug for a nar­row group of pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times